Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q1 2018 (← Previous) (Next →)

Filing Date: May 3, 2018

Total Value ($000): $312,675,947 (100.0% shares, 0.0% debt)

Holdings (8)

CRSP CRISPR Therapeutics AG 67.3%

Value ($000) $210,551,322 Shares 4,606,242 Est. Cost $41.27 Unrealized 0.0%

— Audentes Therapeutics, Inc. 11.6%

Value ($000) $36,198,681 Shares 1,204,615 Est. Cost $17810.00 Unrealized —

— Achaogen, Inc. 5.3%

Value ($000) $16,590,918 Shares 1,281,152 Est. Cost $13050.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 4.6%

Value ($000) $14,422,150 Shares 2,215,384 Est. Cost $20.09 Unrealized -72.0%

— CymaBay Therapeutics, Inc. 4.4%

Value ($000) $13,621,327 Shares 1,048,601 Est. Cost $9830.00 Unrealized —

— Second Sight Medical Products, Inc. 2.8%

Value ($000) $8,626,512 Shares 4,492,975 Est. Cost $1210.00 Unrealized —

— ImmuneDesign Corp. 2.3%

Value ($000) $7,287,093 Shares 2,208,210 Est. Cost $7580.00 Unrealized —

— Clovis Oncology, Inc. 1.7%

Value ($000) $5,377,944 Shares 101,855 Est. Cost $56000.00 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	4,606,242	$210,551,322	67.3%	$41.27	0.0%	Common Stock	H17182108
—	Audentes Therapeutics, Inc.	1,204,615	$36,198,681	11.6%	$17810.00	—	Common Stock	05070R104
—	Achaogen, Inc.	1,281,152	$16,590,918	5.3%	$13050.00	—	Common Stock	004449104
OCUL	Ocular Therapeutix, Inc.	2,215,384	$14,422,150	4.6%	$20.09	-72.0%	Common Stock	67576A100
—	CymaBay Therapeutics, Inc.	1,048,601	$13,621,327	4.4%	$9830.00	—	Common Stock	23257D103
—	Second Sight Medical Products, Inc.	4,492,975	$8,626,512	2.8%	$1210.00	—	Common Stock	81362J100
—	ImmuneDesign Corp.	2,208,210	$7,287,093	2.3%	$7580.00	—	Common Stock	45252L103
—	Clovis Oncology, Inc.	101,855	$5,377,944	1.7%	$56000.00	—	Common Stock	189464100